TAIPEI and SAN DIEGO, Dec. 13,
2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492),
a clinical-stage biopharmaceutical company focused on next
generation DNA Damage Response (DDR) therapeutics for the treatment
of cancer, announced their
Abstract on Cholangiocarcinoma treatment with Silmitasertib
(CX-4945) has been accepted for oral/poster presentation at the
upcoming American Society of Clinical Oncology
Gastrointestinal Cancers Symposium (ASCO GI) in San
Francisco, 15-17 January, 2021. Due to the COVID-19 pandemic, the event will be hosted
virtually.
Senhwa was invited to present positive topline results from
their global phase II trial, evaluating the combination of
Silmitasertib plus Gemcitabine/Cisplatin compared to
Gemcitabine/Cisplatin alone in the frontline treatment of patients
with Cholangiocarcinoma. The trial met its primary endpoint at
a pre-specified interim analysis demonstrating a statistically
significant and clinically meaningful improvement in
progression-free survival (PFS) (P<0.05), and was stopped early
because superior efficacy was demonstrated. PFS was assessed by an
independent statistician.
The full abstract will be made available online
via https://meetinglibrary.asco.org at 5:00 PM
(EST) on 11 January, 2021.
More details of the CCA Treatment Abstract at the 2021 ASCO
GI Symposium:
- Abstract Title: Silmitasertib (CX-4945) in
combination with gemcitabine and cisplatin as first-line treatment
for patients with locally advanced or metastatic
cholangiocarcinoma: A phase Ib/II study.
- Abstract Perm ID: 312
- Session Title: Poster Highlights: Targeted
Approaches and Multimodality
- Session Date and Time: 1/17/2021, 2:30 PM-3:15 PM (PST)
About Silmitasertib
Silmitasertib is a first-in-class small molecule drug that
targets CK2 and acts as a CK2-inhibitor. Silmitasertib is safe and
well-tolerated in humans. To date, three Phase I trials of
Silmitasertib in cancer patients have been completed; currently,
there is one ongoing Phase I and two ongoing Phase II
studies. In December 2016,
Silmitasertib was granted Orphan Drug Designation by the U.S. FDA
for the treatment of Cholangiocarcinoma. In July 2020, Silmitasertib was granted Rare
Pediatric Disease Designation to treat Medulloblastoma by the U.S.
FDA. An eIND was granted by the U.S. FDA on August 27, 2020, to Dr. Rayyan at BUMCP to treat
a patient with severe COVID-19.
About Senhwa Biosciences
Senhwa Biosciences, Inc. is a leading clinical-stage company
focusing on developing first-in-class, next-generation DDR
therapeutics for patients with unmet medical needs in oncology.
Headquartered in Taiwan, with an
operational base in San Diego,
California, Senhwa is well-positioned to oversee the
development of its compounds. Development is currently focused on
two lead products: Silmitasertib (CX-4945) and Pidnarulex
(CX-5461), both with novel mechanisms of action and for multiple
indications. Clinical trials are ongoing in Australia, Canada, United
States, Korea, and Taiwan.
Visit Senhwa Biosciences for more details:
www.senhwabio.com
View original
content:http://www.prnewswire.com/news-releases/senhwa-biosciencess-positive-topline-cholangiocarcinoma-data-abstract-accepted-by-2021-asco-gastrointestinal-cancers-symposium-301191717.html
SOURCE Senhwa Biosciences, Inc.